Intermediate Dose Heparin Thromboprophylaxis among Critically Ill Patients with COVID-19: A Randomised Clinical Trial - PubMed
4 hours ago
- #Clinical Trial
- #COVID-19
- #Thromboprophylaxis
- Intermediate-dose heparin thromboprophylaxis did not significantly improve organ support-free days (OSFDs) in critically ill COVID-19 patients compared to standard low-dose thromboprophylaxis, with a 73.5% probability of improvement, below the 99% superiority threshold.
- No significant difference in hospital survival was observed between groups: 77.1% for intermediate-dose and 76.7% for low-dose heparin.
- Major bleeding rates were low and similar between groups: 1.7% with intermediate-dose and 2.1% with low-dose heparin.